Steven W. Ressler
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Steven W. Ressler has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Jessica D. Austin
Department of Epidemiology, Mayo Clinic College of Medicine and Sciences, Scottsdale, Arizona, USA
2 shared publications - Jon Charles Tilburt
Biomedical Ethics Research Program, Mayo Clinic
2 shared publications - Alexandra Wicker
Mayo Clinic 1 Department of Quantitative Health Sciences Phoenix, Arizona
1 shared publication - Allison Rosenthal
Division of Hematology/Oncology, Mayo Clinic, Phoenix, AZ 85054, USA
1 shared publication - Amanda Courtright
Mayo Clinic 1 Department of Quantitative Health Sciences Phoenix, Arizona
1 shared publication - Brian M. Dougan
Department of Medicine, General Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
1 shared publication
Latest Publications
- 1 September 2026
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 19 (9) , 495-500
Precision Cancer Prevention Needs Both Implementation Science and Ethics
As technological and genomic innovations continue to advance precision cancer prevention, psychosocial, ethical, and operational complexities increasingly accompany their development. Addressing these challenges will require intentional cross-disciplinary collaboration. We argue that the distinct yet complementary lenses of bioethics and implementation science will be crucial as precision cancer prevention technologies move toward clinical integration. We provide a framework for how this joint effort can be accomplished and sustained across the translational pipeline.
- 1 September 2026
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 19 (9) , 495-500
Precision Cancer Prevention Needs Both Implementation Science and Ethics
As technological and genomic innovations continue to advance precision cancer prevention, psychosocial, ethical, and operational complexities increasingly accompany their development. Addressing these challenges will require intentional cross-disciplinary collaboration. We argue that the distinct yet complementary lenses of bioethics and implementation science will be crucial as precision cancer prevention technologies move toward clinical integration. We provide a framework for how this joint effort can be accomplished and sustained across the translational pipeline.
- Open Access
- 28 September 2025
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 15 (10) , 452
Primary Care Clinician Preferences and Perspectives on Multi-Cancer Detection Testing Across an Integrated Healthcare System
Background/Objectives: Multi-cancer detection (MCD) tests have emerged as a promising tool to redefine the landscape of early cancer detection. Implementation of this novel technology will likely fall to primary care clinicians (PCC). The purpose of this study is to characterize and explore differences in PCCs perceptions and preferences towards MCD testing. Methods: Between March and May of 2023, this cross-sectional survey was administered to 281 PCCs, including physicians and advanced care providers practicing within an integrated healthcare system spanning five states. The survey collected data on self-reported characteristics, perceptions of MCD testing, and preferences for learning about MCD testing. Analysis was limited to those with no prior experience with MCD testing (N = 181, response rate 22.8%). Descriptive statistics summarized key variables and chi-square tests assessed differences in perceptions and preferences by key characteristics. Results: Most PCCs were interested in MCD testing (66.3%), but limited knowledge/awareness of MCD testing and confidence to manage patients with a positive test were observed, along with concerns around cost (76.7%) and misuse/poor implementation. The primary preferences for learning about MCD testing were online courses or classroom instruction (64.5%). Significant differences in perceptions and preferences for learning were observed by location, degree, and years in practice. Conclusions: PCCs in our study held positive views towards MCD testing, but gaps and variation in knowledge and confidence towards MCD testing and concerns around the cost and misuse/poor implementation were observed. While efforts to train and educate all PCCs on MCD testing is a critical first step, more research is needed to understand how best to support implementation tailored to individual and system-level needs and characteristics.
- 28 September 2025
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 15 (10) , 452
Open AccessPrimary Care Clinician Preferences and Perspectives on Multi-Cancer Detection Testing Across an Integrated Healthcare System
Background/Objectives: Multi-cancer detection (MCD) tests have emerged as a promising tool to redefine the landscape of early cancer detection. Implementation of this novel technology will likely fall to primary care clinicians (PCC). The purpose of this study is to characterize and explore differences in PCCs perceptions and preferences towards MCD testing. Methods: Between March and May of 2023, this cross-sectional survey was administered to 281 PCCs, including physicians and advanced care providers practicing within an integrated healthcare system spanning five states. The survey collected data on self-reported characteristics, perceptions of MCD testing, and preferences for learning about MCD testing. Analysis was limited to those with no prior experience with MCD testing (N = 181, response rate 22.8%). Descriptive statistics summarized key variables and chi-square tests assessed differences in perceptions and preferences by key characteristics. Results: Most PCCs were interested in MCD testing (66.3%), but limited knowledge/awareness of MCD testing and confidence to manage patients with a positive test were observed, along with concerns around cost (76.7%) and misuse/poor implementation. The primary preferences for learning about MCD testing were online courses or classroom instruction (64.5%). Significant differences in perceptions and preferences for learning were observed by location, degree, and years in practice. Conclusions: PCCs in our study held positive views towards MCD testing, but gaps and variation in knowledge and confidence towards MCD testing and concerns around the cost and misuse/poor implementation were observed. While efforts to train and educate all PCCs on MCD testing is a critical first step, more research is needed to understand how best to support implementation tailored to individual and system-level needs and characteristics.
- Open Access
- 13 March 2025
- Published by SAGE Publications in Journal of Primary Care & Community Health
- Vol. 16
Development of an Undiagnosed Mass Registry: Lessons Learned From Our First 100 Patients
Introduction: The Undiagnosed Mass Clinic (UMC) at our institution is a clinical and research program created to address gaps in the early diagnostic phase of the cancer care continuum for patients with potential malignant neoplasms. All patients referred to the UMC are invited to participate in the UMC registry, which tracks operational and clinical metrics while maintaining a repository of blood and tissue specimens for future research. Methods: We conducted a retrospective cohort study of the first 100 patients enrolled in the UMC registry. We analyzed patient demographics, final diagnoses, and the time from initial consultation to final diagnosis. Results: Most participants were White (86%), non-Hispanic (93%), and married (72%). The mean (SD) age was 64 (13.9) years. The final diagnoses of the masses were categorized as malignant/neoplastic with malignant potential (n = 53), benign (n = 36), or requiring diagnostic surveillance (n = 10). The mean (SD) time from initial consultation to final diagnosis of malignant/neoplastic with malignant potential masses significantly improved from 37.4 (36.6) days for the first 50 participants to 17.3 (19.7) days for the next 50 participants ( P = .006). Conclusions: These initial insights from the UMC registry will help direct future efforts to improve the care of patients with potential malignant neoplasms.
- 13 March 2025
- Published by SAGE Publications in Journal of Primary Care & Community Health
- Vol. 16
Open AccessDevelopment of an Undiagnosed Mass Registry: Lessons Learned From Our First 100 Patients
Introduction: The Undiagnosed Mass Clinic (UMC) at our institution is a clinical and research program created to address gaps in the early diagnostic phase of the cancer care continuum for patients with potential malignant neoplasms. All patients referred to the UMC are invited to participate in the UMC registry, which tracks operational and clinical metrics while maintaining a repository of blood and tissue specimens for future research. Methods: We conducted a retrospective cohort study of the first 100 patients enrolled in the UMC registry. We analyzed patient demographics, final diagnoses, and the time from initial consultation to final diagnosis. Results: Most participants were White (86%), non-Hispanic (93%), and married (72%). The mean (SD) age was 64 (13.9) years. The final diagnoses of the masses were categorized as malignant/neoplastic with malignant potential (n = 53), benign (n = 36), or requiring diagnostic surveillance (n = 10). The mean (SD) time from initial consultation to final diagnosis of malignant/neoplastic with malignant potential masses significantly improved from 37.4 (36.6) days for the first 50 participants to 17.3 (19.7) days for the next 50 participants ( P = .006). Conclusions: These initial insights from the UMC registry will help direct future efforts to improve the care of patients with potential malignant neoplasms.
- Open Access
- 18 February 2017
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 11 (1) , 45
Classical Hodgkin lymphoma masquerading as chronic recurrent multifocal osteomyelitis: a case report
Hodgkin lymphoma is a hematologic malignancy usually confined to lymphatic structures and commonly associated with constitutional symptoms. Bony involvement and musculoskeletal symptoms are uncommon and typically seen in advanced disease. In this case, we report an unusual presentation of classical Hodgkin lymphoma and highlight diagnostic challenges leading to the misdiagnosis and treatment as chronic recurrent multifocal osteomyelitis. A 38-year-old white man presented with lower extremity musculoskeletal pain. Imaging studies revealed multifocal lytic and sclerotic osseous axial lesions. Multiple core needle bone marrow and excisional lymph node biopsies were non-diagnostic. Having met the criteria, a tentative diagnosis of chronic recurrent multifocal osteomyelitis was given. He was treated with non-steroidal anti-inflammatory medications with partial clinical response but had persistent symptoms. A second medical opinion was pursued. An open bone marrow biopsy was performed and yielded a diagnosis of classical Hodgkin lymphoma after 13 months of diagnostic uncertainty. A chemotherapy regimen of doxorubicin, bleomycin, vinblastine, and dacarbazine was instituted with complete symptomatic and radiologic response. This case illustrates diagnostic difficulties of a musculoskeletal presentation of Hodgkin lymphoma, challenges of non-diagnostic bone marrow and lymph node biopsies, and resultant diagnostic delays in delivering a potentially curative therapy. Had the additional open bone marrow biopsy not been performed, the diagnosis and treatment of Hodgkin lymphoma would have been missed.
- 18 February 2017
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 11 (1) , 45
Open AccessClassical Hodgkin lymphoma masquerading as chronic recurrent multifocal osteomyelitis: a case report
Hodgkin lymphoma is a hematologic malignancy usually confined to lymphatic structures and commonly associated with constitutional symptoms. Bony involvement and musculoskeletal symptoms are uncommon and typically seen in advanced disease. In this case, we report an unusual presentation of classical Hodgkin lymphoma and highlight diagnostic challenges leading to the misdiagnosis and treatment as chronic recurrent multifocal osteomyelitis. A 38-year-old white man presented with lower extremity musculoskeletal pain. Imaging studies revealed multifocal lytic and sclerotic osseous axial lesions. Multiple core needle bone marrow and excisional lymph node biopsies were non-diagnostic. Having met the criteria, a tentative diagnosis of chronic recurrent multifocal osteomyelitis was given. He was treated with non-steroidal anti-inflammatory medications with partial clinical response but had persistent symptoms. A second medical opinion was pursued. An open bone marrow biopsy was performed and yielded a diagnosis of classical Hodgkin lymphoma after 13 months of diagnostic uncertainty. A chemotherapy regimen of doxorubicin, bleomycin, vinblastine, and dacarbazine was instituted with complete symptomatic and radiologic response. This case illustrates diagnostic difficulties of a musculoskeletal presentation of Hodgkin lymphoma, challenges of non-diagnostic bone marrow and lymph node biopsies, and resultant diagnostic delays in delivering a potentially curative therapy. Had the additional open bone marrow biopsy not been performed, the diagnosis and treatment of Hodgkin lymphoma would have been missed.
- 31 March 2012
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 87 (3) , 286-289
54-Year-Old Man With Severe Prostatism, Palatal Mass, and History of Pancreatitis
- 31 March 2012
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 87 (3) , 286-289
54-Year-Old Man With Severe Prostatism, Palatal Mass, and History of Pancreatitis